Mirna Therapeutics plans up to $80.5 million initial public offering

Citigroup, Leerink, Oppenheimer and Cantor Fitzgerald are underwriters

By Angela McDaniels

Tacoma, Wash., Aug. 24 – Mirna Therapeutics, Inc. plans to sell up to $80.5 million of common stock in its initial public offering.

The underwriters are Citigroup Global Markets Inc., Leerink Partners LLC, Oppenheimer & Co. Inc. and Cantor Fitzgerald & Co., according to an S-1 filing with the Securities and Exchange Commission.

The underwriters will be granted an over-allotment option.

The company has applied to list its stock on the Nasdaq Global Market under the symbol “MIRN.”

Proceeds will be used for clinical expenses, preclinical studies, working capital and other general corporate purposes.

Mirna is a clinical-stage biopharmaceutical company based in Austin, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.